Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Director · Chief Executive Officer | April 02, 2025 | April 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date April 02, 2025 · Filed April 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-04-02 | Direct | 580,000 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 580,000 · Balance 580,000 F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2025 Filed Apr 4, 2025 16:18 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 580,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000905148-25-001096 · form4.xml · derivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,000 Underlying: Common Stock · 580,000 shares Expires 2035-04-02 F1 · derivative.exercise_date: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 18:56 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 12,500 | $0.81 | $10,120.00 |
DisclosureSEC source: 0000905148-24-003412 · form4.xml · nonDerivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,891 F1 · price: The actual purchase price is $0.809556 per share of Common Stock, which has been rounded due to systematic character limitations. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 16:27 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000905148-24-000970 · form4.xml · derivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:43 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantWarrants (Right to Buy) · Derivative | 37,037 | $0.13 Strike: $2.47 | $4,629.63 |
DisclosureSEC source: 0001140361-23-038881 · form4.xml · derivative · entry 3 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,037 Underlying: Common Stock · 37,037 shares Expires not disclosed F2 · derivative.expiration_date: These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:43 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantCommon Stock | 37,037 | $1.90 | $70,370.30 |
DisclosureSEC source: 0001140361-23-038881 · form4.xml · nonDerivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,391 Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 16:34 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001140361-23-013081 · form4.xml · derivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-03-20 F1 · derivative.exercise_date: One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionClass A Stock · Derivative | 26,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037654 · form4.xml · derivative · entry 3 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Zocca Consulting ApS Disclosed balance after: 0 Underlying: Common Stock · 26,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date. F2 · ownership.nature: The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of his pecuniary interest therein. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 26,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037654 · form4.xml · nonDerivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Zocca Consulting ApS Disclosed balance after: 26,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Class A Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Class A Stock had no expiration date. F2 · ownership.nature: The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of his pecuniary interest therein. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 18:33 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 414,212 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037038 · form4.xml · derivative · entry 1 Zocca Mai-Britt · CIK 0001890736 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,212 Underlying: Common Stock · 414,212 shares Expires 2031-11-04 F1 · derivative.exercise_date: These options vest in 1/48 monthly increments of the vesting commencement date of November 4, 2021, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.